<p><strong>微创医疗科技公司</strong> (HKG:853) 的股东在看到股价在上个季度下跌 17% 后，可能会感到担忧。但这并不改变过去一年回报非常强劲的事实。我们很高兴地报告，在此期间股价上涨了 119%。因此，从这个角度来看最近的价格下跌是很重要的。真正的问题是，公司的发展方向是否正确。</p>
<p>由于该股票在过去一周内为其市值增加了 18 亿港元，让我们看看基础业绩是否推动了长期回报。</p>
<p>这项技术可能会取代计算机：发现 20 只正在努力使量子计算成为现实的股票。</p>
<p>微创医疗目前尚未盈利，因此大多数分析师会关注收入增长，以了解基础业务的增长速度。当一家公司没有盈利时，我们通常希望看到良好的收入增长。一些公司愿意推迟盈利以更快地增长收入，但在这种情况下，人们希望看到良好的收入增长来弥补缺乏盈利。</p>
<p>微创医疗实际上在过去一年中收入减少了 0.7%。我们对股价在过去一年中上涨 119% 感到有些惊讶。这表明市场并不总是关注报告的数字。无论如何，收入下降很可能已经被市场定价。</p>
<p>您可以在下面看到收益和收入随时间的变化（点击图片可以发现确切的数值）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1768089747164?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1768089747164"/></p>
<p>SEHK:853 收益和收入增长 2026 年 1 月 11 日</p>
<p>我们喜欢看到内部人士在过去十二个月中购买股票。尽管如此，未来的收益对当前股东是否赚钱将更为重要。因此，我们建议查看这份 <strong>免费</strong> 报告，显示共识预测。</p>
<h2>不同的视角</h2>
<p>很高兴看到微创医疗的股东在过去一年中获得了 119% 的总股东回报。毫无疑问，这些近期回报远好于过去五年每年 12% 的总股东回报损失。长期损失让我们感到谨慎，但短期的总股东回报增长无疑暗示着更光明的未来。喜欢赚钱的投资者通常会关注内部人士的购买情况，例如支付的价格和购买的总金额。您可以通过点击此链接了解微创医疗的内部人士购买情况。</p>
<p>微创医疗并不是唯一一家内部人士在购买的股票。因此，看看这份 <strong>免费</strong> 的小型公司名单，这些公司在吸引人的估值下被内部人士购买。</p>
<p><em>请注意，本文中引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。</em></p>

微创医疗

<p>微创医疗（HKG:853）在过去一年中为股东带来了令人瞩目的 119% 的回报，尽管在最近一个季度股价下跌了 17%。该股票在过去一周上涨了 8.6%，为其市值增加了 18 亿港元。然而，公司报告的收入下降了 0.7%，这引发了对其长期增长潜力的质疑。过去一年内部人士的增持是一个积极信号，但未来的盈利将对维持股东回报至关重要。总体而言，短期收益与过去五年每年 12% 的长期总回报损失形成了鲜明对比</p>

<p><strong>MicroPort Scientific Corporation</strong> (HKG:853) shareholders might be concerned after seeing the share price drop 17% in the last quarter. But that doesn't change the fact that the returns over the last year have been very strong. We're very pleased to report the share price shot up 119% in that time. So it is important to view the recent reduction in price through that lense. The real question is whether the business is trending in the right direction.</p>
<div class="lb-trans"><p><strong>微创医疗科技公司</strong> (HKG:853) 的股东在看到股价在上个季度下跌 17% 后，可能会感到担忧。但这并不改变过去一年回报非常强劲的事实。我们很高兴地报告，在此期间股价上涨了 119%。因此，从这个角度来看最近的价格下跌是很重要的。真正的问题是，公司的发展方向是否正确。</p>
</div><p>Since the stock has added HK$1.8b to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.</p>
<div class="lb-trans"><p>由于该股票在过去一周内为其市值增加了 18 亿港元，让我们看看基础业绩是否推动了长期回报。</p>
</div><p>This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.</p>
<div class="lb-trans"><p>这项技术可能会取代计算机：发现 20 只正在努力使量子计算成为现实的股票。</p>
</div><p>MicroPort Scientific isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally hope to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.</p>
<div class="lb-trans"><p>微创医疗目前尚未盈利，因此大多数分析师会关注收入增长，以了解基础业务的增长速度。当一家公司没有盈利时，我们通常希望看到良好的收入增长。一些公司愿意推迟盈利以更快地增长收入，但在这种情况下，人们希望看到良好的收入增长来弥补缺乏盈利。</p>
</div><p>MicroPort Scientific actually shrunk its revenue over the last year, with a reduction of 0.7%. We're a little surprised to see the share price pop 119% in the last year. It just goes to show the market doesn't always pay attention to the reported numbers. It's quite likely the revenue fall was already priced in, anyway.</p>
<div class="lb-trans"><p>微创医疗实际上在过去一年中收入减少了 0.7%。我们对股价在过去一年中上涨 119% 感到有些惊讶。这表明市场并不总是关注报告的数字。无论如何，收入下降很可能已经被市场定价。</p>
</div><p>You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).</p>
<div class="lb-trans"><p>您可以在下面看到收益和收入随时间的变化（点击图片可以发现确切的数值）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1768089747164" alt="" original-src="https://images.simplywall.st/asset/chart/26049405-earnings-and-revenue-growth-1-dark-2/1768089747164"/></p>
<p>SEHK:853 Earnings and Revenue Growth January 11th 2026</p>
<div class="lb-trans"><p>SEHK:853 收益和收入增长 2026 年 1 月 11 日</p>
</div><p>We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. So we recommend checking out this <strong>free</strong> report showing consensus forecasts</p>
<div class="lb-trans"><p>我们喜欢看到内部人士在过去十二个月中购买股票。尽管如此，未来的收益对当前股东是否赚钱将更为重要。因此，我们建议查看这份 <strong>免费</strong> 报告，显示共识预测。</p>
</div><h2>A Different Perspective</h2>
<div class="lb-trans"><h2>不同的视角</h2>
</div><p>It's nice to see that MicroPort Scientific shareholders have received a total shareholder return of 119% over the last year. There's no doubt those recent returns are much better than the TSR loss of 12% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. Investors who like to make money usually check up on insider purchases, such as the price paid, and total amount bought. You can find out about the insider purchases of MicroPort Scientific by clicking this link.</p>
<div class="lb-trans"><p>很高兴看到微创医疗的股东在过去一年中获得了 119% 的总股东回报。毫无疑问，这些近期回报远好于过去五年每年 12% 的总股东回报损失。长期损失让我们感到谨慎，但短期的总股东回报增长无疑暗示着更光明的未来。喜欢赚钱的投资者通常会关注内部人士的购买情况，例如支付的价格和购买的总金额。您可以通过点击此链接了解微创医疗的内部人士购买情况。</p>
</div><p>MicroPort Scientific is not the only stock insiders are buying. So take a peek at this <strong>free</strong> list of small cap companies at attractive valuations which insiders have been buying.</p>
<div class="lb-trans"><p>微创医疗并不是唯一一家内部人士在购买的股票。因此，看看这份 <strong>免费</strong> 的小型公司名单，这些公司在吸引人的估值下被内部人士购买。</p>
</div><p><em>Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.</em></p>
<div class="lb-trans"><p><em>请注意，本文中引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。</em></p>
</div>

微创医疗（HKG:853）在过去一年中为股东带来了令人瞩目的 119% 回报，仅在上周就上涨了 8.6%